Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMZMSPF)

Drug Name
Bicalutamide Drug Info
Synonyms
Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
2375
ChEBI ID
CHEMBL409
CAS Number
CAS 90357-06-5
TTD Drug ID
D0V9BD
VARIDT Drug ID
DR00795
INTEDE Drug ID
DR0210
ACDINA Drug ID
D00069

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Starch and sucrose metabolism 1.90 8.84e-3 25/36 (69.44%) HK2;GPI;GYS1;...
Galactose metabolism 1.84 2.65e-2 26/31 (83.87%) PFKM;PFKP;HK2;...
Insulin signaling pathway 1.81 2.36e-2 121/137 (88.32%) FASN;SOCS1;HK2;...
DNA replication 1.80 2.21e-2 34/36 (94.44%) MCM5;MCM2;POLE;...
Fat digestion and absorption 1.77 2.83e-2 35/43 (81.4%) CD36;DGAT1;PNLIP;...
Ribosome biogenesis in eukaryotes 1.75 3.39e-2 52/108 (48.15%) NVL;IMP4;PWP2;...
Fanconi anemia pathway 1.73 4.29e-2 36/54 (66.67%) CENPX;FAAP100;FANCI;...
alpha-Linolenic acid metabolism 1.70 4.97e-2 17/25 (68%) PLA2G4A;FADS2;PLA2G2A;...
NOD-like receptor signaling pathway -1.73 3.11e-2 145/181 (80.11%) VDAC2;OAS3;IKBKE;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.77 2.19e-2 79/89 (88.76%) TICAM1;ZAP70;LCK;...
Rheumatoid arthritis -1.79 2.08e-2 78/93 (83.87%) HLA-DRA;ATP6V1G1;ATP6V1H;...
IL-17 signaling pathway -1.79 2.19e-2 84/94 (89.36%) CCL20;S100A7;FOS;...
Mitophagy -1.82 1.78e-2 56/68 (82.35%) MAPK8;BECN1;TBC1D15;...
Protein export -1.82 1.88e-2 17/23 (73.91%) SRP14;SPCS3;SRP9;...
Salmonella infection -1.83 1.65e-2 198/249 (79.52%) RHOB;DCTN6;PAK3;...
Pathogenic Escherichia coli infection -1.84 1.54e-2 152/197 (77.16%) TRAF6;TMED10;ROCK1;...
Antigen processing and presentation -1.84 1.65e-2 60/78 (76.92%) CD8A;KIR2DL1;HLA-DRB1;...
Legionellosis -1.87 1.10e-2 51/57 (89.47%) TLR5;RAB1A;CXCL3;...
Epithelial cell signaling in Helicobacter pylori infect... -2.03 0.00e+0 62/70 (88.57%) ADAM10;PTPN11;ATP6V1G1;...
Phagosome -2.04 0.00e+0 118/152 (77.63%) DYNC1I1;LAMP2;HLA-A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
SK-N-SH CVCL_0531 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.37uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H